136 related articles for article (PubMed ID: 34924500)
1. miR-26b-5p suppresses chemoresistance in breast cancer by targeting serglycin.
Du Q; Yuan Z; Huang X; Huang Y; Zhang J; Li R
Anticancer Drugs; 2022 Mar; 33(3):308-319. PubMed ID: 34924500
[TBL] [Abstract][Full Text] [Related]
2. SRGN crosstalks with YAP to maintain chemoresistance and stemness in breast cancer cells by modulating HDAC2 expression.
Zhang Z; Qiu N; Yin J; Zhang J; Liu H; Guo W; Liu M; Liu T; Chen D; Luo K; Li H; He Z; Liu J; Zheng G
Theranostics; 2020; 10(10):4290-4307. PubMed ID: 32292495
[No Abstract] [Full Text] [Related]
3. Circ-RNF111 contributes to paclitaxel resistance in breast cancer by elevating E2F3 expression via miR-140-5p.
Zang H; Li Y; Zhang X; Huang G
Thorac Cancer; 2020 Jul; 11(7):1891-1903. PubMed ID: 32445273
[TBL] [Abstract][Full Text] [Related]
4. STAT3 regulates SRGN and promotes metastasis of nasopharyngeal carcinoma through the FoxO1-miR-148a-5p-CREB1 axis.
Wang YL; Ren D; Lu JL; Jiang H; Wei JZ; Lan J; Liu F; Qu SH
Lab Invest; 2022 Sep; 102(9):919-934. PubMed ID: 35562411
[TBL] [Abstract][Full Text] [Related]
5. miR-145-5p attenuates paclitaxel resistance and suppresses the progression in drug-resistant breast cancer cell lines.
Guan X; Guan Y
Neoplasma; 2020 Sep; 67(5):972-981. PubMed ID: 32412771
[TBL] [Abstract][Full Text] [Related]
6. miR-26b-5p suppresses chemoresistance in breast cancer by targeting serglycin: Erratum.
Anticancer Drugs; 2024 Mar; 35(3):316. PubMed ID: 38411026
[No Abstract] [Full Text] [Related]
7. MiR-21-5p enhances the progression and paclitaxel resistance in drug-resistant breast cancer cell lines by targeting PDCD4.
Tao L; Wu YQ; Zhang SP
Neoplasma; 2019 Sep; 66(5):746-755. PubMed ID: 31169019
[TBL] [Abstract][Full Text] [Related]
8. MiR-216a-5p act as a tumor suppressor, regulating the cell proliferation and metastasis by targeting PAK2 in breast cancer.
Zhang Y; Lin P; Zou JY; Zou G; Wang WZ; Liu YL; Zhao HW; Fang AP
Eur Rev Med Pharmacol Sci; 2019 Mar; 23(6):2469-2475. PubMed ID: 30964173
[TBL] [Abstract][Full Text] [Related]
9. MiR-379-5p inhibits the proliferation, migration, and invasion of breast cancer by targeting KIF4A.
Yang K; Li D; Jia W; Song Y; Sun N; Wang J; Li H; Yin C
Thorac Cancer; 2022 Jul; 13(13):1916-1924. PubMed ID: 35608059
[TBL] [Abstract][Full Text] [Related]
10. DSCAM-AS1 promotes tumor growth of breast cancer by reducing miR-204-5p and up-regulating RRM2.
Liang WH; Li N; Yuan ZQ; Qian XL; Wang ZH
Mol Carcinog; 2019 Apr; 58(4):461-473. PubMed ID: 30457164
[TBL] [Abstract][Full Text] [Related]
11. GDPD5, a target of miR-195-5p, is associated with metastasis and chemoresistance in colorectal cancer.
Feng C; Zhang L; Sun Y; Li X; Zhan L; Lou Y; Wang Y; Liu L; Zhang Y
Biomed Pharmacother; 2018 May; 101():945-952. PubMed ID: 29635904
[TBL] [Abstract][Full Text] [Related]
12. MiR-26b-5p inhibits cell proliferation and EMT by targeting MYCBP in triple-negative breast cancer.
Ma S; Wei H; Wang C; Han J; Chen X; Li Y
Cell Mol Biol Lett; 2021 Dec; 26(1):52. PubMed ID: 34895159
[TBL] [Abstract][Full Text] [Related]
13. Knockdown of LINC00665 inhibits proliferation and invasion of breast cancer via competitive binding of miR-3619-5p and inhibition of catenin beta 1.
Lv M; Mao Q; Li J; Qiao J; Chen X; Luo S
Cell Mol Biol Lett; 2020; 25():43. PubMed ID: 32983239
[TBL] [Abstract][Full Text] [Related]
14. Loss of miR-26b-5p promotes gastric cancer progression via miR-26b-5p-PDE4B/CDK8-STAT3 feedback loop.
Xu T; Xie M; Jing X; Jiang H; Wu X; Wang X; Shu Y
J Transl Med; 2023 Feb; 21(1):77. PubMed ID: 36737782
[TBL] [Abstract][Full Text] [Related]
15. Circ_0001667 Promotes Adriamycin Resistance and Malignant Progression via Targeting the miR-193a-5p/Rap2A Molecular Axis in Breast Cancer.
Xu S; Luo W; Li M; Li Q; Hong W; Gao Y; Yang J; Song H; Chen L; Yang Y; Yang C
Clin Breast Cancer; 2023 Jan; 23(1):71-83. PubMed ID: 36289041
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-424-5p enhances chemosensitivity of breast cancer cells to Taxol and regulates cell cycle, apoptosis, and proliferation.
Dastmalchi N; Safaralizadeh R; Hosseinpourfeizi MA; Baradaran B; Khojasteh SMB
Mol Biol Rep; 2021 Feb; 48(2):1345-1357. PubMed ID: 33555529
[TBL] [Abstract][Full Text] [Related]
17. MiR-16-5p suppresses breast cancer proliferation by targeting ANLN.
Wang Z; Hu S; Li X; Liu Z; Han D; Wang Y; Wei L; Zhang G; Wang X
BMC Cancer; 2021 Nov; 21(1):1188. PubMed ID: 34743685
[TBL] [Abstract][Full Text] [Related]
18. Long intergenic non-protein coding RNA 1094 (LINC01094) promotes the progression of breast cancer (BC) by regulating the microRNA-340-5p (miR-340-5p)/E2F transcription factor 3 (E2F3) axis.
Wu X; Kong C; Wu Y
Bioengineered; 2021 Dec; 12(1):9046-9057. PubMed ID: 34657558
[TBL] [Abstract][Full Text] [Related]
19. CEP55 3'-UTR promotes epithelial-mesenchymal transition and enhances tumorigenicity of bladder cancer cells by acting as a ceRNA regulating miR-497-5p.
Yang C; Yang Y; Wang W; Zhou W; Zhang X; Xiao Y; Zhang H
Cell Oncol (Dordr); 2022 Dec; 45(6):1217-1236. PubMed ID: 36374443
[TBL] [Abstract][Full Text] [Related]
20. LINC01140 Targeting miR-452-5p/RGS2 Pathway to Attenuate Breast Cancer Tumorigenesis.
Li X
Dis Markers; 2022; 2022():2434938. PubMed ID: 36299824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
